Inequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost-Utility Analysis.
Sharifa Ezat Wan PutehEllyana Mohamad SelamatAzimatun Noor AizuddinNor Rafeah TumianJameela SatharPublished in: Asian Pacific journal of cancer prevention : APJCP (2022)
Overall, imatinib is more cost-effective than nilotinib for treating CML in Malaysia from the care provider's perspective. The findings demonstrate the importance of cancer drug funding assistance for ensuring that the appropriate treatments are accessible and affordable and that patients with cancer use and benefit from such patient assistance programmes. To establish effective health expenditure, drug distribution inequality should be addressed.
Keyphrases
- healthcare
- chronic myeloid leukemia
- ejection fraction
- newly diagnosed
- public health
- drug induced
- primary care
- adverse drug
- mental health
- bone marrow
- dendritic cells
- squamous cell carcinoma
- risk assessment
- squamous cell
- quality improvement
- immune response
- young adults
- pain management
- chronic pain
- human health
- health promotion
- patient reported
- data analysis